GAF Healthcare

Best Hematologists for Sickle Cell Disease Management in Delhi NCR, India

This page lists 2 sickle cell disease management doctors in Delhi NCR, India. Review each doctor's experience, specialty and hospital, then contact our care team for help with the next step.

Quick answer

This page lists 2 sickle cell disease management doctors in Delhi NCR, India. Review each doctor's experience, specialty and hospital, then contact our care team for help with the next step.

About Sickle Cell Disease Management doctors in Delhi NCR, India

This directory is based on doctors currently listed in GAF Healthcare's registry. Clinical suitability varies by patient; a doctor should review your history and investigations before any treatment decision.

Sickle Cell Disease Management doctors

Image not available Featured

Dr. Garima Nirmal

MBBS, MD, DM (Haematology)
Senior Consultant — Paediatric Haematology · Specialty: Paediatric Haematologist
Apollo Hospitals Indraprastha New Delhi, India10+ Years experience
Why consider this doctor?
  • 10+ years of experience in Paediatric Haematologist
  • Senior Consultant, Paediatric Haematology, Apollo Hospitals Indraprastha, New Delhi
  • Specialist in paediatric haematological disorders with focus on bone marrow transplantation and complex blood disorders management
Expertise & Procedures
  • Bone Marrow Biopsy and Aspiration
  • Pediatric Leukemia Management and Chemotherapy
  • Sickle Cell Disease Management
  • Thalassemia Treatment Planning
  • Aplastic Anemia Immunosuppressive Therapy
View all procedures →
Paediatric Haematologist Experience: 10+ YearsHospital Affiliation: Apollo Hospitals IndraprasthaHospital accreditation: JCI, NABH
View Profile Book a Consultation
Image not available

Dr. Neha Rastogi

MBBS, DCH, DNB, Fellowship, Fellowship, Fellowship
Senior Consultant — Pediatric Hematology · Specialty: Pediatric Hematologist
Medanta — The Medicity Gurugram, India10+ Years experience
Why consider this doctor?
  • 10+ years of experience in Pediatric Hematologist
  • Senior Consultant, Pediatric Hematology and Bone Marrow Transplant, Medanta — The Medicity, Gurugram — Present
  • Training Fellowship, Bone Marrow Transplantation and Leukemia, Premier Institutes (India and Canada)
Expertise & Procedures
  • Bone Marrow Transplantation (BMT) in Children
  • Haploidentical Stem Cell Transplantation
  • Hematopoietic Stem Cell Mobilization and Collection
  • Management of Acute Leukemia in Children
  • Treatment of Thalassemia Major and Intermedia
View all procedures →
Pediatric Hematologist Experience: 10+ YearsHospital Affiliation: Medanta — The MedicityHospital accreditation: JCI, NABH
View Profile Book a Consultation

Hospitals where these doctors practise

Apollo Hospitals🇮🇳 New Delhi, India
Starting from$1,500

Apollo Hospitals

Est. 1983
JCI — Joint Commission International accreditationNABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation
Sickle Cell Disease ManagementHematologyCardiac SurgeryCardiology
1+
Doctors for Sickle Cell Disease Management
4.9
1240 reviews
1000+
Beds
43+
Years Since Founded
Dr. Garima Nirmal
View Hospital Profile Enquire / Get Free Opinion
Medanta - The Medicity🇮🇳 Gurgaon, India
Starting from$1,500

Medanta - The Medicity

Est. 2009
JCI — Joint Commission International accreditationNABH — National Accreditation Board for Hospitals & Healthcare Providers accreditation
Sickle Cell Disease ManagementHematologyCardiac SurgeryCardiology
1+
Doctors for Sickle Cell Disease Management
4.9
2150 reviews
1600+
Beds
17+
Years Since Founded
Dr. Neha Rastogi
View Hospital Profile Enquire / Get Free Opinion

Why consider treatment in India?

Many international patients consider India for sickle cell disease treatment for several reasons, including:

More affordable estimates

Competitive indicative costs compared with many other countries, for similar clinical standards.

Internationally accredited hospitals

Hospitals experienced in treating international patients.

Experienced specialists

Doctors who regularly manage similar cases.

Care coordination support

A team to help with planning, medical translation and follow-up.

About the Procedure

What is Sickle Cell Disease Management?

Sickle Cell Disease (SCD) management ranges from long-term supportive care with hydroxyurea and transfusions to curative Allogeneic Bone Marrow/Stem Cell Transplant (BMT), which replaces the patient's defective bone marrow with healthy donor stem cells. Curative transplant is typically recommended for patients with severe, recurrent complications (strokes, acute chest syndrome, frequent crises) who have a suitable donor. India offers internationally accredited BMT centers with experienced pediatric and adult hematology teams at significantly lower cost than Western countries.

Who may be considered?

Sickle Cell Disease Management may be considered after a qualified specialist reviews your reports and medical history. Suitability varies from person to person and must be assessed by your treating doctor.

How does it work?

Uses stem cells from an HLA-matched sibling donor, offering the highest cure rates and lowest complication rates among transplant options for sickle cell disease.

3 approaches available for this procedure:

Matched Sibling Donor Allogeneic HSCT

Gold Standard

Uses stem cells from an HLA-matched sibling donor, offering the highest cure rates and lowest complication rates among transplant options for sickle cell disease.

Comprehensive Investigations

Estimated cost: $800 - $2,500

HLA typing (patient and siblings), CBC with reticulocyte count, hemoglobin electrophoresis, MRI brain, transcranial Doppler, chest X-ray, liver and kidney function tests, ferritin level, viral serology (HIV, hepatitis B/C), ECG and echocardiogram

Treatment / Procedure Estimate

Estimated cost in India: $25,000 - $38,000

Stay in India

Pre-procedure stay (outside hospital): ~5-7 days
Hospitalisation: ~25-30 days
Recovery period (outside hospital): ~90 days recommended
Total stay: approx 100-120 days

Usually Included in Hospital Package

  • Pre-transplant conditioning chemotherapy
  • Stem cell infusion and inpatient BMT unit stay
  • Donor workup and stem cell harvest
  • Post-transplant monitoring and supportive medications
  • Coordinator and interpreter assistance

Usually Not Included

  • Long-term immunosuppressant medications after discharge
  • Accommodation for caregiver outside hospital
  • Treatment of graft-versus-host disease if it occurs
  • International and local travel costs
  • Extended follow-up visits beyond 3 months

Recovery and follow-up

Post-transplant recovery involves close monitoring for engraftment, infection, and graft-versus-host disease over 2-3 months, followed by gradual tapering of immunosuppressants and periodic blood tests; non-transplant management requires ongoing follow-up every few months to adjust hydroxyurea dosing and monitor organ function.

Risks

Transplant-related risks include graft-versus-host disease, graft failure, infection due to immunosuppression, and organ toxicity from conditioning chemotherapy; non-transplant management carries risks of disease progression, chronic organ damage, and transfusion-related iron overload.

Alternatives

Alternatives to curative transplant include long-term hydroxyurea therapy, chronic blood transfusion programs with iron chelation, and emerging gene therapy options, all of which manage symptoms without the risks associated with transplantation.

What we need to prepare a formal estimate

Share whatever you have — the care team will confirm the final checklist after reviewing your case.

Reports required

  • Complete blood count (CBC) with reticulocyte count
  • Hemoglobin electrophoresis report confirming SCD genotype
  • HLA typing report of patient and potential family donors
  • MRI/MRA brain and transcranial Doppler results
  • Liver, kidney, and cardiac function test reports
  • History of prior transfusions, crises, and hospitalizations
  • Iron overload assessment (serum ferritin, T2* MRI if available)
  • Current medication list including hydroxyurea dosage

Patient information needed

  • Patient's age, weight, and current clinical status
  • Frequency and severity of vaso-occlusive crises
  • History of stroke, acute chest syndrome, or organ damage
  • Availability of potential sibling or family donors
  • Vaccination and infection history
  • Any prior transfusions and known blood group antibodies
  • Family medical history related to sickle cell disease
  • Preferred travel dates and accompanying caregiver details

Costs shown are indicative planning estimates based on typical pricing across leading Indian hospitals. They are not a quote — actual pricing depends on your case complexity, hospital choice, and length of stay. Share your reports for a personalized estimate.

Want a formal estimate?

Share your reports and patient information so our care coordination team can review your case.

How this directory is built

Doctors are matched using the specialty, location, condition (Sickle Cell Disease Management) and procedure (Sickle Cell Disease Management) recorded in their profiles. Inclusion is not an endorsement and does not guarantee a treatment outcome.

Need help with the next step?

Share your needs with our care coordination team for information about doctors and hospitals.

Common questions

FAQs about Sickle Cell Disease Management in Delhi NCR, India

What is Sickle Cell Disease?
Sickle cell disease is a group of inherited red blood cell disorders caused by a mutation in the haemoglobin gene, resulting in haemoglobin S (HbS), which distorts red blood cells into a stiff sickle shape. The most common and typically most severe form is haemoglobin SS disease (HbSS), though other variants such as HbSC and HbS-beta thalassaemia also fall under the SCD umbrella.
What are the symptoms and health risks of Sickle Cell Disease?
Common manifestations include recurrent episodes of severe pain (vaso-occlusive or 'sickle cell' crises), fatigue and anaemia, swelling of the hands and feet (dactylitis, particularly in young children), frequent infections, delayed growth, and vision problems. More serious acute complications — including acute chest syndrome, stroke, and splenic sequestration — can be life-threatening and require urgent medical attention. Because many of these symptoms overlap with other conditions, experiencing them does not confirm a diagnosis of sickle cell disease; formal testing is always required.
How is Sickle Cell Disease diagnosed?
Diagnosis is typically confirmed through haemoglobin electrophoresis or high-performance liquid chromatography (HPLC), which identify the specific haemoglobin variants present, and is often first detected through newborn screening programmes. Further investigations used to assess disease burden and guide management include full blood count (to gauge baseline haemoglobin and reticulocyte count), transcranial Doppler ultrasound (to screen for stroke risk in children), organ function tests (renal, hepatic, pulmonary), and, where transplant is being considered, HLA typing of the patient and potential donors. Genotyping confirms the precise SCD subtype — such as HbSS, HbSC, or HbS-beta⁰/beta⁺ thalassaemia — which strongly influences prognosis and treatment planning.
How is Sickle Cell Disease treated?
Treatment is tailored to disease severity, complication history, age, and the availability of suitable donors, and ranges from ongoing medical management through to curative procedures. For patients with severe or refractory disease, allogeneic bone marrow (stem cell) transplantation currently represents the only established curative option and is evaluated on a case-by-case basis by a specialist team. All treatment decisions — including whether and when to pursue transplantation — should be made in close consultation with a qualified clinician who has reviewed the individual's full clinical picture.
Can Sickle Cell Disease be treated without a procedure?
Medical management forms the cornerstone of care for the majority of patients and includes hydroxyurea (hydroxycarbamide), which reduces the frequency of painful crises and acute chest syndrome in eligible patients; regular blood transfusion programmes to lower HbS levels and reduce stroke risk; prophylactic antibiotics and vaccinations to reduce infection risk; and pain management protocols for acute crises. Newer disease-modifying agents — including voxelotor and crizanlizumab — may be recommended in certain cases, subject to availability and individual clinical assessment. These approaches do not cure the disease but can significantly reduce complications and improve quality of life.
When is Sickle Cell Disease Management considered for Sickle Cell Disease?
Sickle Cell Disease Management may be considered only when it is appropriate for the confirmed diagnosis and the expected benefit outweighs the individual risks. The decision may depend on symptom severity, investigation results, previous treatment, overall health and the patient's goals. A specialist should discuss alternatives and recovery before any procedure is planned.
Which doctor treats Sickle Cell Disease?
Sickle cell disease is typically managed by a haematologist specialising in haemoglobinopathies or a sickle cell disease specialist; in cases where transplantation is being considered, a haematologist with expertise in bone marrow transplantation (BMT physician) leads the evaluation. Paediatric patients are usually under the care of a paediatric haematologist, and ongoing multidisciplinary input — from nephrologists, pulmonologists, neurologists, ophthalmologists, and pain specialists — is often necessary given the multi-organ nature of the disease.
How do I choose a doctor for Sickle Cell Disease?
When comparing providers, prioritise centres with a dedicated sickle cell or haemoglobinopathy programme, demonstrable experience in allogeneic transplantation (including matched unrelated and haploidentical donor protocols) if transplant is relevant to your case, and access to a full multidisciplinary team for long-term follow-up and complication management. It is also worth asking specifically about the centre's experience managing patients with your SCD subtype and complication history, as outcomes can vary meaningfully between programmes.
What documents do international patients need to share for a medical evaluation?
Share a concise medical summary, symptom timeline, previous diagnoses, investigation and imaging reports, procedure or biopsy reports where relevant, current medicines, allergies and related treatment records. Provide clear copies with translations when needed. The reviewing doctor may request additional information before giving an opinion.
How does GAF Healthcare help international patients plan treatment in India?
Our care coordination team can review the initial information, help identify suitable doctors and hospitals, request a medical opinion where available, explain next steps and indicative cost information, and support practical planning before travel. A remote opinion does not replace an in-person examination or emergency care.
WhatsApp Us